(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 137.82% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Verastem's revenue in 2025 is $10,000,000.On average, 3 Wall Street analysts forecast VSTM's revenue for 2025 to be $703,102,443, with the lowest VSTM revenue forecast at $532,372,530, and the highest VSTM revenue forecast at $901,017,338. On average, 3 Wall Street analysts forecast VSTM's revenue for 2026 to be $3,103,773,038, with the lowest VSTM revenue forecast at $2,800,876,752, and the highest VSTM revenue forecast at $3,686,448,078.
In 2027, VSTM is forecast to generate $7,209,168,434 in revenue, with the lowest revenue forecast at $6,106,323,213 and the highest revenue forecast at $9,308,796,264.